OBJECTIVE: This study sought to determine if relative neutropenia (RN) following six cycles of paclitaxel/carboplatin could serve as a prognostic factor in patients with ovarian cancer. DESIGN: A single institution, retrospective study. SETTING: Tertiary academic referral center, Seoul, Korea Population. A total of 179 patients who underwent primary cytoreductive surgery, followed by six cycles of paclitaxel/carboplatin chemotherapy to treat epithelial ovarian cancer. METHODS: Relative neutropenia was defined by an absolute neutrophil count < 1000 neutrophils/mm(3) at chemotherapy cycle nadir. To eliminate the effects of dose reduction (DR) and schedule delay (SD) on the outcome of analysis, 49 patients who had this were excluded, and a subset analysis of 130 patients who received standard doses and schedules of chemotherapy was performed. MAIN OUTCOME MEASURES: Progression free and overall survival. RESULTS: The median progression free survival (PFSs) of neutropenic and non-neutropenic patients was 34 and 22 months, respectively; the median overall survival (OS) times were 67 and 56 months, respectively, with no significant differences in PFS and OS (p = 0.26, 0.59). Multivariate analysis revealed that stage, clear cell histology, and > or =1 cm residual tumor mass were independent prognostic predictors, while RN was not. In the subset analysis confined to the patients without DR and SD, the results were not changed. CONCLUSION: Chemotherapy-induced neutropenia was not a significant prognostic indicator in ovarian cancer patients treated with paclitaxel/carboplatin as first-line chemotherapy.
OBJECTIVE: This study sought to determine if relative neutropenia (RN) following six cycles of paclitaxel/carboplatin could serve as a prognostic factor in patients with ovarian cancer. DESIGN: A single institution, retrospective study. SETTING: Tertiary academic referral center, Seoul, Korea Population. A total of 179 patients who underwent primary cytoreductive surgery, followed by six cycles of paclitaxel/carboplatin chemotherapy to treat epithelial ovarian cancer. METHODS: Relative neutropenia was defined by an absolute neutrophil count < 1000 neutrophils/mm(3) at chemotherapy cycle nadir. To eliminate the effects of dose reduction (DR) and schedule delay (SD) on the outcome of analysis, 49 patients who had this were excluded, and a subset analysis of 130 patients who received standard doses and schedules of chemotherapy was performed. MAIN OUTCOME MEASURES: Progression free and overall survival. RESULTS: The median progression free survival (PFSs) of neutropenic and non-neutropenicpatients was 34 and 22 months, respectively; the median overall survival (OS) times were 67 and 56 months, respectively, with no significant differences in PFS and OS (p = 0.26, 0.59). Multivariate analysis revealed that stage, clear cell histology, and > or =1 cm residual tumor mass were independent prognostic predictors, while RN was not. In the subset analysis confined to the patients without DR and SD, the results were not changed. CONCLUSION: Chemotherapy-induced neutropenia was not a significant prognostic indicator in ovarian cancerpatients treated with paclitaxel/carboplatin as first-line chemotherapy.
Authors: S Banerjee; G Rustin; J Paul; C Williams; S Pledge; H Gabra; G Skailes; A Lamont; A Hindley; G Goss; E Gilby; M Hogg; P Harper; E Kipps; L-A Lewsley; M Hall; P Vasey; S B Kaye Journal: Ann Oncol Date: 2012-10-05 Impact factor: 32.976
Authors: C K Lee; H Gurney; C Brown; R Sorio; N Donadello; G Tulunay; W Meier; M Bacon; J Maenpaa; E Petru; N Reed; V Gebski; E Pujade-Lauraine; S Lord; R J Simes; M Friedlander Journal: Br J Cancer Date: 2011-07-12 Impact factor: 7.640
Authors: Andreas Carus; Howard Gurney; Val Gebski; Paul Harnett; Rina Hui; Richard Kefford; Nicholas Wilcken; Morten Ladekarl; Hans von der Maase; Frede Donskov Journal: J Transl Med Date: 2013-08-15 Impact factor: 5.531